APA (7th ed.) Citation

JJ, P., K, O., GW, L., G, B., JH, P., HB, K., . . . EG, K. (2023). Defining regorafenib as a senomorphic drug: Therapeutic potential in the age-related lung disease emphysema. Experimental & molecular medicine, 55(4), 794. https://doi.org/10.1038/s12276-023-00966-6

Chicago Style (17th ed.) Citation

JJ, Park, Oh K, Lee GW, Bang G, Park JH, Kim HB, Kim JY, Shin EY, and Kim EG. "Defining Regorafenib as a Senomorphic Drug: Therapeutic Potential in the Age-related Lung Disease Emphysema." Experimental & Molecular Medicine 55, no. 4 (2023): 794. https://doi.org/10.1038/s12276-023-00966-6.

MLA (9th ed.) Citation

JJ, Park, et al. "Defining Regorafenib as a Senomorphic Drug: Therapeutic Potential in the Age-related Lung Disease Emphysema." Experimental & Molecular Medicine, vol. 55, no. 4, 2023, p. 794, https://doi.org/10.1038/s12276-023-00966-6.